MapLight Therapeutics initiated with a Buy at Stifel

Stifel initiated coverage of MapLight Therapeutics (MPLT) with a Buy rating and $28 price target The firm sees the company as a potential second-mover in the muscarinic space. Despite the slower than expected launch of Cobenfy, the muscarinic space represents a very large revenue opportunity, the analyst tells investors in a research note. Stifel believes MapLight’s ML-007C-MA offers potential avenues for differentiation, specifically around more convenient dosing and improved tolerability.